Exploratory Study of NS-065/NCNP-01 in DMD

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

August 31, 2015

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

NS-065/NCNP-01

"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"

Trial Locations (1)

1878551

National Center of Neurology and Psychiatry, Kodaira

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Nippon Shinyaku Co., Ltd.

INDUSTRY

lead

National Center of Neurology and Psychiatry, Japan

OTHER